Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | mRNA-2752 + Tremelimumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tremelimumab | CP-675,206|Ticilimumab|CP-675206 | CTLA4 Antibody 22 Immune Checkpoint Inhibitor 147 | Tremelimumab (CP-675206) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937). | |
mRNA-2752 | mRNA2752|mRNA 2752 | mRNA-2752 is a lipid nanoparticle encapsulated combination of messenger RNAs encoding IL-36gamma, IL-23, and OX40L (TNFSF4), which stimulate the immune system (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03739931 | Phase I | mRNA-2752 mRNA-2752 + Tremelimumab Durvalumab + mRNA-2752 | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies | Recruiting | USA | 1 |